FFGO: Fortress Financial Group | PGPM: Pilgrim Petroleum | MSGI: MSGI Security Solutions | PVCT: Provectus Pharmaceuticals

FFGO: Fortress Financial Group, Inc. - Outstanding Stock Confirmation
Company Confirms the Number of Shares of Outstanding Stock

Aug 26, 2008 3:26:00 PM

NEW YORK, NY -- (MARKET WIRE) -- 08/26/08 -- Fortress Financial Group, Inc. (PINKSHEETS: FFGO) confirms that the Company's total number of outstanding shares of Common Stock are in the amount of 27,922,377,817; as confirmed in a number of Form 8-K filings in respect of the Company's substantial repurchases of its shares of Common Stock, that being coupled with the cancellation of certain shares of the Company's Common Stock issued in respect of "Signing bonuses."

The Company is preparing all of the stock cancellation paperwork for submission to the Transfer Agent. The Company categorically states, confirms and undertakes that our number of outstanding shares as published by ourselves is indeed 100% accurate and correct. The Company expects that the Transfer Agent will be in a position to verify that our calculations are correct, by no later than early next week. The Transfer Agent is in no position to verify our number of outstanding shares of Common Stock until such time as they receive the all of the requisite paperwork and stock certificates, from ourselves, for immediate cancellation.

Alan Santini, the CEO of Fortress Financial Group, Inc., "confirmed that he clearly understood that this was a top priority for the Company at this time due to the imminent announcement of the Record Date of the Extraordinary Dividend." Alan Santini added "that he would ensure that the Transfer Agent was in possession of all cancellation requests within days."

Various stockholders who are required to file both Form 13(g) and Form 13(d) filings in respect of their stockholdings in the Company; have indicated that they will do so, upon confirmation from the Transfer Agent that our published outstanding shares of Common Stock are correct.

PGPM: Pilgrim Petroleum Announces Re-Alignment of Its Corporate Strategy

Aug 26, 2008 8:30:00 AM
DALLAS, TX -- (MARKET WIRE) -- 08/26/08 -- Pilgrim Petroleum Corporation (PINKSHEETS: PGPM) (FRANKFURT: PHV), announces an internal re-alignment and reorganization of its business as a result of the latest transaction event with Implantable Vision Ltd. Pilgrim Petroleum Corporation will redirect its Corporate Strategy by exclusively focusing on its Oilfield Service Operations. This consolidation on Pilgrim's activities will provide and stabilize a leaner corporation, easier to streamline operations to improve cost controls and focus on revenue generation. These are the key elements of Pilgrim's ongoing productivity initiative. Pilgrim is also expected to generate significant operating efficiencies and accelerate the delivery of strategic technologies to the marketplace. As the company moves forward, it plans to improve its competitive position within the Oilfield Service Industry among independent oil and gas companies on domestic onshore basins of West Texas and Mid Continent regions, looking into a more extended service with more powerful capabilities to ensure high quality of service, safety, security and environment.

Pilgrim together with its subsidiary American Petroleum Corporation will expand its customer portfolio and continue its corporate strategy to provide customers with all of the products and services they need before, during and after drilling operations.

Rafael Pinedo, President and CEO of Pilgrim Petroleum Corporation, commented, "The reorganization represents the next step in our process to re-position Pilgrim for continued success in today's Energy Industry. We have defined our longer-term strategy and areas of focus; now we are aligning our organization and leadership to execute our business plan."

MSGI Security Solutions Announces Acceleration of Sub-Contracting Agreement to $100 Million Annually

Aug 26, 2008 11:00:00 AM

View Additional ProfilesNEW YORK, Aug. 26 /PRNewswire-FirstCall/ -- MSGI Security Solutions, Inc. (OTC Bulletin Board: MSGI) "MSGI" today reported an acceleration of certain sub-contracting agreements with its Korean business partners resulting in projected gross revenues of $100 million annually. The business acceleration is expected to begin in September.

On October 26, 2006, MSGI entered into a sub-contracting agreement with Hyundai Syscomm Corp. to provide wireless video surveillance solutions. On May 23, 2007, MSGI entered into a sub-contracting and distribution agreement with Apro Media Corp. to provide commercial security services to a Fortune 100 defense contractor. Apro Media Corp. would potentially earn 16 million shares of MSGI over the course of seven years in exchange for the business. On August 22, 2008 MSGI negotiated an acceleration of both sub-contracting agreements with Hirsch Capital Corp., the San Francisco based private equity firm operating Hyundai Syscomm and Apro Media.

Under the accelerated terms, MSGI would ramp up to a platform generating approximately $100 million in annual gross revenue supporting several of the largest commercial businesses in Korea. There will be additional revenue from sales to the Fortune 100 defense contractor as well. As part of this expansion MSGI will become the beneficiary of various technology transfers. These new assets are expected to include Hi-Definition Video Surveillance systems, Hi-Definition DVR systems and emerging RFID Technology. Based upon the binding commitment to expand MSGI to a run rate of $100 million in annual gross revenue, Hirsch Capital will have the right to earn shares of MSGI as indicated in the sub-contracting and distribution agreement referenced above.

MSGI executive staff will be increased to support the new business and technical operations will be relocated to Northern California within the next few months. Subsequent progress reports on the status of this business acceleration will be issued throughout the remainder of the current quarter.

PVCT: Professor John F. Thompson to Present at Perspectives in Melanoma XII, Thursday October 2, 2008

Conference to be Held at the Steigenberger Kurhaus Hotel in The Hague, Netherlands, October 2-4, 2008
Aug 26, 2008 9:38:00 AM
Copyright Business Wire 2008


Provectus Pharmaceuticals, Inc. (OTC BB: PVCT), a development-stage oncology and dermatology biopharmaceutical company, announced today that the Lead Investigator for its phase 2 melanoma study, Professor John F. Thompson, MD, will present clinical data on PV-10 at the Perspectives in Melanoma XII meeting at The Hague, The Netherlands. Professor Thompson's presentation, entitled "PV-10 Chemoablation of cutaneous and subcutaneous metastatic melanoma," is scheduled for the afternoon symposium on emerging therapies scheduled for approximately 2:20 pm local time on Thursday October 2nd, 2008.

"The presentation by Professor Thompson is expected to report data from the completed phase 1 clinical trial, as well as providing an update on the current phase 2 study," noted Craig Dees, PhD, CEO of Provectus.

Dees continued, "Professor Thompson is one of the world's foremost authorities on melanoma treatment and the global lead investigator for our PV-10 clinical trials. He recently made a presentation on July 25, 2008, at the inaugural Sydney Cancer Conference 2008, which can be accessed via our website (www.pvct.com). In addition, 'The 7:30 Report,' a highly acclaimed Australian Broadcasting Corporation current affairs program airing in Australia, ran a story entitled: 'Melanoma breakthrough: a simple and less invasive cure' on the treatment of melanoma with PV-10, which is also accessible on Provectus' website.

Dees continued, "We announced recently that the first twenty-five percent (20 of 80) of melanoma subjects have been treated in the phase 2 study, with enrollment continuing at centers in Brisbane and Sydney, Australia, and at the M.D. Anderson Cancer Center in Houston, TX. We expect to announce additional sites in Australia and the U.S. in the coming months."

According to the American Cancer Society, in 2008 more than 62,000 people are expected to be diagnosed with melanoma in the in the US , the most serious form of skin cancer, leading to over 8,000 deaths this year.